Showing 2341-2350 of 5644 results for "".
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi
- Zeiss Announces FDA Clearance of the Quatera 700 Phaco Devicehttps://modernod.com/news/zeiss-announces-fda-clearance-of-the-quatera-700-phaco-technology/2480779/Zeiss announced that the FDA has cleared the Quatera 700, which includes the Zeiss patented Quattro Pump designed to deliver chamber stability independent of IOP and flow. “What excites me the most about the Quatera 700 is the Quattro pump’
- Market Scope: Robotic Vitrectomy Debate Still Rages for Retina Surgeonshttps://modernod.com/news/market-scope-robotic-vitrectomy-debate-still-rages-for-retina-surgeons/2480773/The future of robotic vitrectomy continues to be top of mind for retina surgeons, with panelists at nearly every major retina meeting in 2021 debating the topic—and without reaching co
- Study Lays Foundation for Establishing Base Editing as a One-Time, Durable Treatment for Inherited Retinal Degenerationhttps://modernod.com/news/study-lays-foundation-for-establishing-base-editing-as-a-one-time-durable-treatment-for-inherited-retinal-degeneration/2480766/A new University of California, Irvine-led study indicates base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis (LCA) patients. “Our findings demo
- Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at ASCRShttps://modernod.com/news/orasis-pharmaceuticals-to-present-new-data-on-novel-presbyopia-candidate-at-ascrs/2480764/Orasis Pharmaceuticals announced that it will present new data on its novel eye drop candidate, CSF-1, at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) annual meeting being held April 22-26 in Washington, D.C. "We look forward to these present
- Opus Enters Strategic Collaboration with Resilience for AAV-based Gene Therapy Development and Manufacturing for Inherited Retinal Diseaseshttps://modernod.com/news/opus-enters-strategic-collaboration-with-resilience-for-aav-based-gene-therapy-development-and-manufacturing-for-inherited-retinal-diseases/2480756/Opus Genetics announced a strategic manufacturing services agreement with National Resilience, a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, to support the development and manufacturing of Opus’ pipeline. Resilience
- AXIM Biotech Develops Rapid Quantitative Tear Test for MMP-9, An Inflammatory Biomarker of Dry Eye Diseasehttps://modernod.com/news/axim-biotech-develops-rapid-quantitative-tear-test-for-mmp-9-an-inflammatory-biomarker-of-dry-eye-disease/2480753/AXIM Biotechnologies announced that it has successfully developed a rapid quantitative tear test for MMP-9, an inflammatory biomarker for dry eye disease. "Dry eye disease, though widespread, is under-diagnosed, in part because symptoms do not always
- Novartis Receives European Commission Approval of Beovu for Diabetic Macular Edema (DME)https://modernod.com/news/novartis-announces-european-commission-approval-of-beovu-for-diabetic-macular-edema-dme/2480740/Novartis announced that the European Commission (EC) has approved Beovu (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). Today’s approval in DME represents the second indication for Beovu granted by the EC, which was first approved for the
- Olympic Ophthalmics Announces FDA Clearance and Availability of Its Next-Generation iTEAR100 Neurostimulation Devicehttps://modernod.com/news/olympic-ophthalmics-announces-fda-clearance-and-availability-of-its-next-generation-itear100-neurostimulation-device-expanded-patent-portfolio-and-further-clinical-studies/2480737/Olympic Ophthalmics announced that the FDA has granted 510(K) clearence for its second-generation iTEAR100 device, a prescription neuromodulation therapy to acutely increase tear production in adult patients over a 30-day period. The second-generation device is a connected device o
- Nova Eye President Appointed to American Glaucoma Society (AGS) Foundation Advisory Boardhttps://modernod.com/news/nova-eye-president-appointed-to-american-glaucoma-society-ags-foundation-advisory-board/2480735/Nova Eye Medical has announced that Joe Bankovich, President of Nova Eye, has been appointed as an industry representative to the American Glaucoma Society Foundation Advisory Board. Established in 2011 and comprising over 1500 members, the American Glaucoma Society Foundation runs